Genentech Under Consideration

Roche/Genentech's Second Move to Protect Lucentis Franchise - OIS

Roche/Genentech's Second Move to Protect Lucentis Franchise - OIS

Quick Reference Guide: Managing Applicant Tracking in Workday as

Quick Reference Guide: Managing Applicant Tracking in Workday as

From Wall Street, a Warning About Cancer-Drug Prices - WSJ

From Wall Street, a Warning About Cancer-Drug Prices - WSJ

Roche - Roche's Hemlibra reduced treated bleeds by 96 percent

Roche - Roche's Hemlibra reduced treated bleeds by 96 percent

A Case Study of Mosunetuzumab in Relapsed/Refractory Non

A Case Study of Mosunetuzumab in Relapsed/Refractory Non

Analysis Of The Trastuzumab Biosimilar Market As Herceptin

Analysis Of The Trastuzumab Biosimilar Market As Herceptin

Genentech plans to double Solano Co  pharmaceutical plant output

Genentech plans to double Solano Co pharmaceutical plant output

Roche - Growing a pool of talent for emerging markets

Roche - Growing a pool of talent for emerging markets

Genentech's Therapeutic Strategy for Indolent Non-Hodgkin's Lymphoma

Genentech's Therapeutic Strategy for Indolent Non-Hodgkin's Lymphoma

Genentech plans to double Solano Co  pharmaceutical plant output

Genentech plans to double Solano Co pharmaceutical plant output

GAZYVA® (obinutuzumab) Adverse Reactions for First-Line CLL

GAZYVA® (obinutuzumab) Adverse Reactions for First-Line CLL

Anti-VEGF intervention in neovascular AMD: benefits and risks

Anti-VEGF intervention in neovascular AMD: benefits and risks

Novel paradigms in systemic lupus erythematosus - The Lancet

Novel paradigms in systemic lupus erythematosus - The Lancet

Melissa Redd is a featured guest expert on Consciously Speaking

Melissa Redd is a featured guest expert on Consciously Speaking

Innovation vs Financialization: an Analysis on the United States as

Innovation vs Financialization: an Analysis on the United States as

Angiogenesis Modulators Market Outlook (2019-2025) | Celgene

Angiogenesis Modulators Market Outlook (2019-2025) | Celgene

Global Injectable Anticoagulants Market 2019 Pfizer, Otsuka

Global Injectable Anticoagulants Market 2019 Pfizer, Otsuka

Oliver B Stauch's research works | Genentech, California and other

Oliver B Stauch's research works | Genentech, California and other

Convelo, Genentech Join Forces to Develop MS Remyelination Therapies

Convelo, Genentech Join Forces to Develop MS Remyelination Therapies

Considerations from the Innovation and Quality Induction Working

Considerations from the Innovation and Quality Induction Working

United Kingdom - The Intellectual Property Review - Edition 7 - TLR

United Kingdom - The Intellectual Property Review - Edition 7 - TLR

Managing GAZYVA® (obinutuzumab) Infusion Reactions | R/R FL

Managing GAZYVA® (obinutuzumab) Infusion Reactions | R/R FL

The use of clinical study reports to enhance the quality of

The use of clinical study reports to enhance the quality of

Management of Immunotherapy-Related Toxicities, Version 1 2019, NCCN

Management of Immunotherapy-Related Toxicities, Version 1 2019, NCCN

Genentech v Hoechst and Sanofi-Aventis (C-567/14) - SnIPpets Fieldfisher

Genentech v Hoechst and Sanofi-Aventis (C-567/14) - SnIPpets Fieldfisher

Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq,  Avastin

Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin

Support & Financial Resources for Patients| RITUXAN® (rituximab) HCP

Support & Financial Resources for Patients| RITUXAN® (rituximab) HCP

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big

Dying patients want easier access to experimental drugs  Here's why

Dying patients want easier access to experimental drugs Here's why

2016 Genentech Oncology Trend Report,DNA strand Genentech_4C_no tagline

2016 Genentech Oncology Trend Report,DNA strand Genentech_4C_no tagline

Fertility endpoints in NHP chronic tox studies for mAbs

Fertility endpoints in NHP chronic tox studies for mAbs

Prescription Drugs Manufactured By Genentech, Inc  - Recall Guide

Prescription Drugs Manufactured By Genentech, Inc - Recall Guide

Development of a robust RNA-based classifier to accurately determine

Development of a robust RNA-based classifier to accurately determine

Genentech Joins Mission Local to Turn Buses Into Art! - Mission Local

Genentech Joins Mission Local to Turn Buses Into Art! - Mission Local

United Kingdom - The Intellectual Property Review - Edition 7 - TLR

United Kingdom - The Intellectual Property Review - Edition 7 - TLR

Considerations from the Innovation and Quality Induction Working

Considerations from the Innovation and Quality Induction Working

A Comprehensive Study Exploring Chemotherapy Market : Key Players in

A Comprehensive Study Exploring Chemotherapy Market : Key Players in

San Francisco Burton High School Women in Tech Panel Discussion: 2-2

San Francisco Burton High School Women in Tech Panel Discussion: 2-2

Systematic Review: Targeting HER2 in Bladder Cancer - IOS Press

Systematic Review: Targeting HER2 in Bladder Cancer - IOS Press

Institutional Case Study: Genentech's Café B33

Institutional Case Study: Genentech's Café B33

A Virtual Reality View  Personalized Cancer Therapy: Targeting the

A Virtual Reality View Personalized Cancer Therapy: Targeting the

Genentech v Hoechst and Sanofi-Aventis (C-567/14) - SnIPpets Fieldfisher

Genentech v Hoechst and Sanofi-Aventis (C-567/14) - SnIPpets Fieldfisher

ACEP's tPA Debate Goes Public - Emergency Physicians Monthly

ACEP's tPA Debate Goes Public - Emergency Physicians Monthly

Prescription Drugs Manufactured By Genentech, Inc  - Recall Guide

Prescription Drugs Manufactured By Genentech, Inc - Recall Guide

Basel, 11 January 2018 An Open Letter to the Haemophilia Community

Basel, 11 January 2018 An Open Letter to the Haemophilia Community

Genentech Celebrates Bon Appétit and Other Suppliers

Genentech Celebrates Bon Appétit and Other Suppliers

Innovation vs Financialization: an Analysis on the United States as

Innovation vs Financialization: an Analysis on the United States as

Genentech Interview Questions | Glassdoor

Genentech Interview Questions | Glassdoor

Genentech Betting on a Device Approach to a Blockbuster Ophthalmic

Genentech Betting on a Device Approach to a Blockbuster Ophthalmic

Challenges and approaches to implementing master/basket trials in

Challenges and approaches to implementing master/basket trials in

Adopting agile mind-sets to transform pharma development | McKinsey

Adopting agile mind-sets to transform pharma development | McKinsey

Large-cell neuroendocrine carcinoma of lung with epidermal growth

Large-cell neuroendocrine carcinoma of lung with epidermal growth

Celltrion and Teva Sue Genentech Over Trastuzumab, Rituximab Patents

Celltrion and Teva Sue Genentech Over Trastuzumab, Rituximab Patents

Innovation in Chemistry, Manufacturing, and Controls-A Regulatory

Innovation in Chemistry, Manufacturing, and Controls-A Regulatory

Increasing Awareness About High Dose Radiation (HDR) Monotherapy

Increasing Awareness About High Dose Radiation (HDR) Monotherapy

REWRITING TREATMENTS FOR PATIENTS WITH CANCER AND OTHER SERIOUS DISEASES

REWRITING TREATMENTS FOR PATIENTS WITH CANCER AND OTHER SERIOUS DISEASES

2018 New Drugs Approvals: An All-Time Record, And A Watershed

2018 New Drugs Approvals: An All-Time Record, And A Watershed

Genentech Herceptin formulation patents invalid | Gowling WLG

Genentech Herceptin formulation patents invalid | Gowling WLG

Outcomes-Based Contracting with Value-Based Insurance Design

Outcomes-Based Contracting with Value-Based Insurance Design

Genentech Defends Herceptin Dosing Patents Before PTAB | News

Genentech Defends Herceptin Dosing Patents Before PTAB | News

Definitive Additional Soliciting Materials

Definitive Additional Soliciting Materials

Avidity-based binding to HER2 results in selective killing of HER2

Avidity-based binding to HER2 results in selective killing of HER2

MillennialEYE | 2016 FDA Approvals | Drugs

MillennialEYE | 2016 FDA Approvals | Drugs

GENENTECH INC (Form Type: SC 14D9/A, Filing Date: 03/12/2009)

GENENTECH INC (Form Type: SC 14D9/A, Filing Date: 03/12/2009)

fast-track Archives - Page 58 of 69 - BioPharma Global

fast-track Archives - Page 58 of 69 - BioPharma Global

An Examination of the Right to Try Act of 2017 and Industry's

An Examination of the Right to Try Act of 2017 and Industry's

Sean Brusky on taking value into consideration when developing cancer drugs

Sean Brusky on taking value into consideration when developing cancer drugs

ACEP's tPA Debate Goes Public - Emergency Physicians Monthly

ACEP's tPA Debate Goes Public - Emergency Physicians Monthly

Clinical Biospecimens and Central Lab Solutions | Summit for

Clinical Biospecimens and Central Lab Solutions | Summit for

pred (Roche Pharma Research & Early Development) gred (Genentech

pred (Roche Pharma Research & Early Development) gred (Genentech

Genentech: Seeing the Unseen with Artificial Intelligence

Genentech: Seeing the Unseen with Artificial Intelligence

Prescription Drugs Manufactured By Genentech, Inc  - Recall Guide

Prescription Drugs Manufactured By Genentech, Inc - Recall Guide

Examining patent applications for biotechnological inventions - GOV UK

Examining patent applications for biotechnological inventions - GOV UK

SAHA Enhances Synaptic Function and Plasticity In Vitro but Has

SAHA Enhances Synaptic Function and Plasticity In Vitro but Has

FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia

FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia

A UC Santa Cruz Professor May Have Actually Developed an HIV Vaccine

A UC Santa Cruz Professor May Have Actually Developed an HIV Vaccine

Scale-Down Model Development in ambr systems: An Industrial Perspective

Scale-Down Model Development in ambr systems: An Industrial Perspective

Genentech Interview Questions | Glassdoor

Genentech Interview Questions | Glassdoor

Kazia Therapeutics unveils fresh clinical trial for its brain cancer

Kazia Therapeutics unveils fresh clinical trial for its brain cancer